PainChek General Discussion, page-1906

As you know Brightwater was involved in the original validation studies of PainChek. 

Did you buy any 2.8c shares yesterday? I was waiting for 2.5c and so missed it. Maybe @Davisite did, as I know he was looking.

I am a fan of the mosaic method of investing, whereby one learns as much as possible about the business as possible, because the small things can add up to a totality greater than the sum of the parts. I learned that a week ago we met with Ken Wyatt in Sydney to discuss how PainChek can help with improving aged care in Australia.

My current thinking is that PainChek will really become the gold standard in the aged care industry to manage pain. The current fear of equity dilution is justified, but not to the extent of a halving of the share price. Take a look at who the top shareholders and option holders are and ask yourself if the business is being managed for all stakeholders.